PE20240372A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents
Anticuerpos y composiciones anti-nkg2aInfo
- Publication number
- PE20240372A1 PE20240372A1 PE2023003150A PE2023003150A PE20240372A1 PE 20240372 A1 PE20240372 A1 PE 20240372A1 PE 2023003150 A PE2023003150 A PE 2023003150A PE 2023003150 A PE2023003150 A PE 2023003150A PE 20240372 A1 PE20240372 A1 PE 20240372A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- nkg2a antibodies
- nkg2a
- antibodies
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta invencion se refiere a anticuerpos anti-NKG2A y a metodos para usarlos para aumentar la inmunidad en un paciente que lo necesita y en el tratamiento del cancer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163195470P | 2021-06-01 | 2021-06-01 | |
PCT/EP2022/064703 WO2022253805A1 (en) | 2021-06-01 | 2022-05-31 | Anti-nkg2a antibodies and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240372A1 true PE20240372A1 (es) | 2024-03-05 |
Family
ID=82117230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023003150A PE20240372A1 (es) | 2021-06-01 | 2022-05-31 | Anticuerpos y composiciones anti-nkg2a |
Country Status (15)
Country | Link |
---|---|
US (1) | US12012450B2 (es) |
EP (1) | EP4347651A1 (es) |
JP (1) | JP2024520577A (es) |
KR (1) | KR20240016991A (es) |
CN (1) | CN117460748A (es) |
AR (1) | AR126001A1 (es) |
AU (1) | AU2022286617A1 (es) |
BR (1) | BR112023024772A2 (es) |
CA (1) | CA3222040A1 (es) |
CO (1) | CO2023015982A2 (es) |
IL (1) | IL308695A (es) |
MX (1) | MX2023014320A (es) |
PE (1) | PE20240372A1 (es) |
TW (1) | TW202313683A (es) |
WO (1) | WO2022253805A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024140820A1 (zh) * | 2022-12-28 | 2024-07-04 | 浙江博锐生物制药有限公司 | 抗nkg2a抗体及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
DK2374818T3 (da) * | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
WO2009092805A1 (en) | 2008-01-24 | 2009-07-30 | Novo Nordisk A/S | Humanized anti-human nkg2a monoclonal antibody |
SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
KR102598068B1 (ko) * | 2014-10-23 | 2023-11-06 | 이나뜨 파르마 에스.에이. | 항-nkg2a 제제를 이용하는 암 치료 |
WO2017046774A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
CA3020647A1 (en) | 2016-04-12 | 2017-10-19 | Symphogen A/S | Anti-tim-3 antibodies and compositions |
CN111153995B (zh) * | 2018-11-07 | 2020-12-25 | 上海怀越生物科技有限公司 | Nkg2a抗体及其制备方法和应用 |
BR112021009111A2 (pt) * | 2018-11-16 | 2021-08-24 | Bristol-Myers Squibb Company | Anticorpos anti-nkg2a e usos dos mesmos |
-
2022
- 2022-05-31 WO PCT/EP2022/064703 patent/WO2022253805A1/en active Application Filing
- 2022-05-31 JP JP2023573662A patent/JP2024520577A/ja active Pending
- 2022-05-31 EP EP22732067.8A patent/EP4347651A1/en active Pending
- 2022-05-31 BR BR112023024772A patent/BR112023024772A2/pt unknown
- 2022-05-31 MX MX2023014320A patent/MX2023014320A/es unknown
- 2022-05-31 TW TW111120182A patent/TW202313683A/zh unknown
- 2022-05-31 US US17/828,740 patent/US12012450B2/en active Active
- 2022-05-31 AU AU2022286617A patent/AU2022286617A1/en active Pending
- 2022-05-31 CN CN202280039227.XA patent/CN117460748A/zh active Pending
- 2022-05-31 IL IL308695A patent/IL308695A/en unknown
- 2022-05-31 PE PE2023003150A patent/PE20240372A1/es unknown
- 2022-05-31 KR KR1020237043690A patent/KR20240016991A/ko unknown
- 2022-05-31 CA CA3222040A patent/CA3222040A1/en active Pending
- 2022-05-31 AR ARP220101426A patent/AR126001A1/es unknown
-
2023
- 2023-11-23 CO CONC2023/0015982A patent/CO2023015982A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL308695A (en) | 2024-01-01 |
AU2022286617A1 (en) | 2023-12-21 |
BR112023024772A2 (pt) | 2024-02-15 |
CN117460748A (zh) | 2024-01-26 |
MX2023014320A (es) | 2023-12-13 |
TW202313683A (zh) | 2023-04-01 |
CA3222040A1 (en) | 2022-12-08 |
JP2024520577A (ja) | 2024-05-24 |
WO2022253805A1 (en) | 2022-12-08 |
KR20240016991A (ko) | 2024-02-06 |
CO2023015982A2 (es) | 2024-01-15 |
US12012450B2 (en) | 2024-06-18 |
EP4347651A1 (en) | 2024-04-10 |
US20220389100A1 (en) | 2022-12-08 |
AR126001A1 (es) | 2023-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210488A1 (es) | Anticuerpos especificos para gucy2c y sus usos | |
CO2019004003A2 (es) | Composiciones y anticuerpos anti-lag-3 | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
CL2019002850A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3. | |
PE20180268A1 (es) | Composiciones que comprenden cepas bacterianas | |
PE20210167A1 (es) | Proteinas de union multiespecificas y mejoras con estas | |
AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
CL2016000538A1 (es) | Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos | |
CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
CO2023015982A2 (es) | Anticuerpos anti-nkg2a y composiciones | |
CU20160133A7 (es) | Anticuerpos anti-mcam y métodos de uso asociados | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
CL2022002833A1 (es) | Anticuerpos anti-flt3 y composiciones | |
AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
CO2019007686A2 (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo | |
CO2019007205A2 (es) | Usos terapéuticos de un polvo de insectos | |
CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
CL2020002624A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia |